Watanabe M, Hagino Y
Department of Psychopharmacology, Tokyo Institute of Psychiatry, Japan.
Eur J Pharmacol. 1999 Feb 12;367(1):19-23. doi: 10.1016/s0014-2999(98)00936-4.
Previous studies have shown that sertindole (1-[2-[4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-piperidinyl]ethyl ]-2 imidazolidinone), an atypical antipsychotic drug that is a potent 5-HT2A and dopamine D2 receptor antagonist, preferentially affects mesocorticolimbic rather than mesostriatal dopamine neurons. Using in vivo microdialysis in conscious rats, we investigated the effects of sertindole on dopamine release and metabolism in the striatum and the medial prefrontal cortex. Systemic administration of sertindole dose dependently enhanced dopamine release in the medial prefrontal cortex and the striatum to the same extent.
先前的研究表明，舍吲哚（1-[2-[4-[5-氯-1-(4-氟苯基)-1H-吲哚-3-基]-1-哌啶基]乙基]-2-咪唑烷酮），一种非典型抗精神病药物，是强效的5-HT2A和多巴胺D2受体拮抗剂，优先作用于中脑皮质边缘系统而非中脑纹状体多巴胺神经元。我们采用清醒大鼠体内微透析技术，研究了舍吲哚对纹状体和内侧前额叶皮质中多巴胺释放及代谢的影响。舍吲哚全身给药后，剂量依赖性地同等程度增强了内侧前额叶皮质和纹状体中的多巴胺释放。
